This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of -35.29% and -4.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates
by Zacks Equity Research
Sage Therapeutics (SAGE) delivered earnings and revenue surprises of +17.71% and +80.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
Legend Biotech (LEGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 9.09% and 6.47%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 7.25% and 8.06%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 42.86% and 4.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use
by Zacks Equity Research
EC expands the label of Ultragenyx's Evkeeza in the EU to treat younger patients aged 6 months to 5 years suffering from a rare cholesterol disorder.
Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in the VNDA stock now may turn out to be a prudent move.
KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates
by Zacks Equity Research
Kodiak stock skyrockets 271% in six months on the back of positive updates from the tarcocimab program for treating retinal vascular diseases.
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
by Sundeep Ganoria
We present three small biotech stocks, which according to Wall Street analysts, have upside potential for 2025.
New Strong Buy Stocks for November 14th
by Zacks Equity Research
VNDA, TSQ, SPPJY, VMEO and TBI have been added to the Zacks Rank #1 (Strong Buy) List on November 14, 2024.
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More
by Zacks Equity Research
VNDA and JAZZ are in the spotlight following regulatory and pipeline updates, respectively.
VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises
by Zacks Equity Research
Vanda's board of directors unanimously rejects the second takeover proposal from Cycle Group Holdings. Shares rise on the news.
Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More
by Zacks Equity Research
Biohaven and Zevra are in the spotlight following positive updates on key candidates.
VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis
by Zacks Equity Research
The FDA issues a complete response letter to Vanda's new drug application for tradipitant for treating symptoms in gastroparesis.
Vanda (VNDA) Surges 24.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Vanda (VNDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Vanda (VNDA) Rises on Positive Data From Motion Sickness Study
by Zacks Equity Research
Vanda's (VNDA) tradipitant appears effective in preventing vomiting associated with motion sickness in a second phase III study. Stock rises on the news.
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Zymeworks (ZYME) delivered earnings and revenue surprises of -35.48% and 44.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Vanda Pharmaceuticals (VNDA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Vanda Pharmaceuticals (VNDA) reachead $4.56 at the closing of the latest trading day, reflecting a -1.51% change compared to its last close.
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Vanda's (VNDA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed drugs and certain pipeline and regulatory updates.
Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up
by Zacks Equity Research
Vanda's (VNDA) board of directors unanimously rejects takeover proposals from Future Pak to acquire all outstanding shares of Vanda. Shares rise on the news.
Investors Heavily Search Vanda Pharmaceuticals Inc. (VNDA): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Vanda (VNDA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Vanda Pharmaceuticals (VNDA) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
Vanda Pharmaceuticals (VNDA) concluded the recent trading session at $4.06, signifying a -1.46% move from its prior day's close.
Vanda Pharmaceuticals (VNDA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
Vanda Pharmaceuticals (VNDA) closed at $4.28 in the latest trading session, marking a -1.83% move from the prior day.
AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors
by Zacks Equity Research
FDA approves AstraZeneca (AZN) and partner Daiichi Sankyo's Enhertu for HER2-expressing metastatic cancers based on data from three phase II studies.